Prevalence and Clinical Significance of Drug-Drug and Drug-Dietary Supplement Interactions among Patients Admitted for Cardiothoracic Surgery in Greece

被引:11
|
作者
Spanakis, Marios [1 ,2 ]
Melissourgaki, Maria [3 ]
Lazopoulos, George [3 ,4 ]
Patelarou, Athina E. [1 ]
Patelarou, Evridiki [1 ]
机构
[1] Hellen Mediterranean Univ, Fac Hlth Sci, Dept Nursing, GR-71004 Iraklion, Greece
[2] Fdn Res & Technol Hellas FORTH, Inst Comp Sci, Computat Biomed Lab, GR-70013 Iraklion, Greece
[3] Univ Hosp Heraklion, Cardiothorac Surg Div, GR-71500 Iraklion, Greece
[4] Univ Crete, Sch Med, GR-71500 Iraklion, Greece
关键词
drug– drug interactions; pharmacokinetic interactions; pharmacodynamic interactions; herb interactions; food interactions; cardiovascular disease; cardiothoracic surgery; CARDIOVASCULAR-DISEASE; ALTERNATIVE MEDICINE; COMPLEMENTARY; GRAPEFRUIT; WEIGHT; FRUIT; UNIT;
D O I
10.3390/pharmaceutics13020239
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Drug interactions represent a major issue in clinical settings, especially for critically ill patients such as those with cardiovascular disease (CVD) who require cardiothoracic surgery (CTS) and receive a high number of different medications. Methods: A cross-sectional study aimed at evaluating the exposure and clinical significance of drug-drug (DDIs) and drug-dietary supplement interactions (DDSIs) in patients admitted for CTS in the University Hospital of Crete Greece. DDIs were evaluated regarding underlying pharmacological mechanisms upon admission, preoperation, postoperation, and discharge from CTS clinic. Additionally, upon admission, the use of dietary supplements (DSs) and if patients had informed their treating physician that they were using these were recorded with subsequent analysis of potential DDSIs with prescribed medications. Results: The study employed 76 patients who were admitted for CTS and accepted to participate. Overall, 166 unique DDIs were identified, with 32% of them being related to pharmacokinetic (PK) processes and the rest (68%) were related to possible alterations of pharmacodynamic (PD) action. CVD medications and drugs for central nervous system disorders were the most frequently interacting medications. In total, 12% of the identified DDIs were of serious clinical significance. The frequency of PK-DDIs was higher during admission and discharge, whereas PD-DDIs were mainly recorded during pre- and postoperation periods. Regarding DS usage, 60% of patients were using DSs and perceived them as safe, and the majority had not informed their treating physician of this or sought out medical advice. Analysis of medical records showed 30 potential combinations with prescribed medications that could lead in DDSIs due to modulation of PK or PD processes, and grapefruit juice consumption was involved in 38% of them. Conclusions: An increased burden of DDIs and DDSIs was identified mostly upon admission for patients in CTS clinics in Greece. Healthcare providers, especially prescribing physicians in Greece, should always take into consideration the possibility of DDIs and the likely use of DS products by patients to promote their well-being; this should only be undertaken after receiving medical advice and an evidenced-based evaluation.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 50 条
  • [31] Assessing Drug-Drug Interaction Potential among Patients Admitted to Surgery Departments in Three Palestinian Hospitals
    Rabba, Abdullah K.
    Abu Hussein, Ayeshe M.
    Abu Sbeih, Bayan K.
    Nasser, Somaya, I
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [32] Polypharmacy and drug-drug interactions among patients with ulcerative colitis
    Esteban, Figueroa
    Overby, M.
    Brian, Behm
    Takahiro, Nakamura
    Brian, Wentworth
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S25 - S26
  • [33] Potential drug-drug interactions among hospitalised TB patients
    Thomas, L.
    Kurian, S. J.
    Mukherjee, N.
    Thomas, R. B.
    Keerthanaa, B.
    Chaithra
    Sekhar, S. M.
    Subeesh, V.
    Varma, M.
    Banerjee, M.
    Rao, M.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (12) : 1137 - +
  • [34] Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?
    Noor, Sidra
    Ismail, Mohammad
    Ali, Zahid
    BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (1):
  • [35] Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19
    Alfehaid, Lama S.
    Farah, Subrina
    Omer, Azza
    Weber, Brittany N.
    Alkhezi, Omar
    Tawfik, Yahya M. K.
    Shah, Amil M.
    Libby, Peter
    Buckley, Leo F.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [36] Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?
    Sidra Noor
    Mohammad Ismail
    Zahid Ali
    BMC Pharmacology and Toxicology, 20
  • [37] Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics
    Georgiev, Kaloyan D.
    Hvarchanova, Nadezhda
    Stoychev, Elitsa
    Kanazirev, Branimir
    SCIENCE PROGRESS, 2022, 105 (01)
  • [38] Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials
    Sawsan Rashdan
    Hui Yang
    Tri Le
    Christopher Selby
    David E. Gerber
    Carlos A. Alvarez
    Clinical Drug Investigation, 2021, 41 : 161 - 167
  • [39] Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists
    Baniasadi, Shadi
    Farzanegan, Behrooz
    Alehashem, Maryam
    ANNALS OF INTENSIVE CARE, 2015, 5 : 1 - 8
  • [40] Clinical Relevance of Drug-Drug Interactions in Hospitalized Dermatology Patients
    Ganeva, Maria
    Gancheva, Tanya
    Troeva, Jeni
    Kiriyak, Nataliya
    Hristakieva, Evgenya
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2013, 22 (04): : 555 - 563